To the best of our knowledge, this is the first study to comprehensively investigate the PD-1/PD-L1/PD-L2 axis in endometrial cancer by combining gene expression profiling in tumor tissue with the assessment of surface expression on immune cell subsets and the measurement of soluble forms in plasma. This evidence concerns the gene PDCD1 and endometrial cancer.